Published in Ann Surg Oncol on March 01, 1998
Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg (2001) 1.36
Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann Surg Oncol (2011) 0.97
Melanoma in pediatric, adolescent, and young adult patients. Semin Oncol (2009) 0.89
Sentinel lymph node biopsy progress in surgical treatment of cancer. Langenbecks Arch Surg (2004) 0.87
Combined endoscopic and open inguinal dissection for malignant melanoma. Langenbecks Arch Surg (2003) 0.85
Treatment strategy for cutaneous malignant melanoma. Int J Clin Oncol (2005) 0.80
Laparoscopic iliac and iliofemoral lymph node resection for melanoma. Surg Endosc (2012) 0.77
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA (1996) 4.13
Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol (1999) 3.74
Human beta-nerve growth factor gene sequence highly homologous to that of mouse. Nature (1983) 3.17
Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg (1998) 2.90
A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer (1985) 2.82
Knowledge and attitude on screening mammography among low-literate, low-income women. Cancer (1996) 2.81
Lyme arthritis in the Hunter Valley. Med J Aust (1982) 2.68
Implementation of new surgical technology: outcome measures for lymphatic mapping of breast carcinoma. Ann Surg Oncol (1999) 2.36
Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation (2001) 2.24
Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology (2008) 2.17
The orderly progression of melanoma nodal metastases. Ann Surg (1994) 2.16
Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer (1998) 2.11
Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma of the lower extremity. Plast Reconstr Surg (1999) 2.02
A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol (2000) 1.98
In support of sentinel node biopsy as a standard of care for patients with malignant melanoma. Dermatol Surg (2000) 1.95
Pathologic examination of the sentinel lymph node in malignant melanoma. Am J Surg Pathol (1999) 1.68
Clinical, electrophysiologic, and pathologic evidence for sensory abnormalities in ALS. Neurology (2007) 1.68
Radioguided surgery for the ultrastaging of the patient with melanoma. Cancer J Sci Am (1998) 1.67
Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol (2001) 1.66
Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer. Ann Surg Oncol (1998) 1.64
Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA (1998) 1.62
Detection of submicroscopic lymph node metastases in patients with melanoma. Arch Surg (1991) 1.61
Radiologic, endoscopic, and surgical considerations of melanoma metastatic to the gastrointestinal tract. Surgery (1984) 1.59
Sentinel-lymph-node biopsy for breast cancer--not yet the standard of care. N Engl J Med (1998) 1.54
Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer (1998) 1.54
The effects of postinjection massage on the sensitivity of lymphatic mapping in breast cancer. J Am Coll Surg (2001) 1.53
Microstaging of breast cancer patients using cytokeratin staining of the sentinel lymph node. Ann Surg Oncol (1999) 1.50
Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis. Surgery (1995) 1.49
Malignant melanoma and pregnancy. Cancer (1985) 1.47
Influence of physician communication on newly diagnosed breast patients' psychologic adjustment and decision-making. Cancer (1994) 1.46
Translational control during the acute phase response. Ferritin synthesis in response to interleukin-1. J Biol Chem (1990) 1.43
Age as a prognostic factor in the malignant melanoma population. Ann Surg Oncol (1994) 1.43
Analysis of residual cancer after diagnostic breast biopsy: an argument for fine-needle aspiration cytology. Ann Surg Oncol (1995) 1.42
Cutaneous lymphatic drainage in patients with grossly involved nodal basins. Ann Surg Oncol (1999) 1.42
Decreased mortality of severe acute pancreatitis after proximal cytokine blockade. Ann Surg (1995) 1.41
Monoamine oxidase and catechol-O-methyltransferase activity in hamster and rat insulinomas. Diabetologia (1979) 1.41
Randomized controlled trial of ultrasonic dissection versus standard surgical technique in open left hemicolectomy or total gastrectomy. Br J Surg (2011) 1.41
Mobilization of iron from endocytic vesicles. The effects of acidification and reduction. J Biol Chem (1990) 1.41
Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer (1996) 1.41
Panic disorder and depression in female alcoholics. J Clin Psychiatry (1988) 1.40
Lymphatic mapping and sentinel node biopsy in the management of high-risk melanoma. J Am Acad Dermatol (1998) 1.38
Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol (2000) 1.38
Randomized prospective evaluation of a novel technique for biopsy or lumpectomy of nonpalpable breast lesions: radioactive seed versus wire localization. Ann Surg Oncol (2001) 1.38
Chlorhexidine. An adjunct to periodontal therapy. J Periodontol (1986) 1.37
Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg (1995) 1.35
Tempol, a stable free radical, is a novel murine radiation protector. Cancer Res (1992) 1.34
Stuies on the interaction of substrate and monovalent and divalent cations with pyruvate kinase. Biochemistry (1966) 1.33
Lethal "thin" malignant melanoma. Identifying patients at risk. Ann Surg (1988) 1.30
Postoperative cell mediated immune response is better preserved after laparoscopic vs open colorectal resection in humans. Surg Endosc (2003) 1.28
Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma. Am J Surg (1991) 1.28
Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg (2001) 1.28
Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. J Clin Oncol (1999) 1.27
Touch preparation cytology of breast lumpectomy margins with histologic correlation. Arch Surg (1991) 1.27
Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg (1983) 1.26
Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery (2001) 1.26
Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol (2000) 1.21
Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg (1994) 1.16
The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer (2000) 1.15
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia (2010) 1.14
The role of sentinel lymph node biopsy in breast cancer. J Am Coll Surg (1999) 1.14